Frequently Asked Questions

Yes. Royal Raymond Rife (1888-1971) was an American inventor and researcher who worked in San Diego, California. His existence is documented in U.S. Patent records (#1,727,618), newspaper archives (San Diego Tribune, Los Angeles Times), the Smithsonian Institution Annual Report (1944), and cemetery records (Mount Hope Cemetery, San Diego). One of his microscopes survives at the Science Museum in London.

Contemporary sources reference a clinical trial conducted under the USC Special Medical Research Committee, headed by Dr. Milbank Johnson. Newspaper coverage from the era mentions the work. However, the original USC committee records have disappeared, and no peer-reviewed publication of the trial results exists. We have documentation that the trial was discussed and referenced at the time, but the primary clinical records are lost.

The simplest answer is that Rife's central scientific and clinical claims were never established through reproducible studies. Legal disputes, the collapse of Beam Rays, and John Crane's prosecution are part of the documentary record; bribery, coordinated suppression, and deliberate destruction claims largely come from later supportive accounts. The Fitzgerald statement criticized institutional treatment of some proposed cancer remedies, but it did not test or validate Rife's devices.

No modern approval validates a general 'Rife principle.' Tumor Treating Fields and TheraBionic use defined mechanisms, exposure conditions, indications, and evidence that differ from Rife's claimed Mortal Oscillatory Rates. The FDA approved specific TTFields devices for particular cancers and granted TheraBionic a Humanitarian Device Exemption in September 2023 for a narrow liver-cancer indication. Those decisions support those devices and uses only; they do not validate Rife's frequencies or modern 'Rife machines.'

A 1944 Smithsonian annual-report article described extraordinary magnification and resolution claims for Rife's microscope and said it could observe living specimens. That publication records the claims; it is not an independent performance test. The Science Museum in London holds a surviving microscope, but later examination did not reproduce the claimed optical performance. Whether missing parts, alignment, or the original claims explain the gap remains unresolved.

Morris Fishbein was a physician and medical editor who led JAMA from 1924 to 1949 and became a prominent public voice for the AMA. The AMA was convicted in a federal antitrust case involving organized medicine's opposition to a prepaid medical group. Fishbein also lost a 1949 libel case brought by Harry Hoxsey. Claims that Fishbein tried to buy Rife's technology or personally directed a campaign against it come from supportive Rife accounts and are not established by the institutional records cited here.

Benedict Fitzgerald prepared a 1953 staff statement about obstacles faced by several proposed cancer remedies. Representative Charles Kersten placed it in the Congressional Record on August 3, 1953. It contains serious allegations and criticism of the AMA and other institutions, but entry in the Congressional Record is not congressional endorsement, a clinical trial, or validation of the therapies discussed. Rife is not named in the statement.

We don't know. No modern device replicates Rife's original technology exactly. Most use different frequency ranges, output methods, and modulation schemes. The CAFL and other frequency lists derive from the Crane-era devices (1950s-60s), which used frequencies approximately 1/10th of Rife's originals. No rigorous clinical trials have been conducted on modern Rife devices. They are not FDA-approved for disease treatment. Individual reports of benefit exist, but so do reports of no effect.

Rife's original frequencies (1930s) operated in the range of 139 kHz to 1.6 MHz, generated as sidebands on a ~3.3 MHz carrier wave. In the 1950s, John Crane and John Marsh modified the technology, apparently misunderstanding the sideband method. They lowered the audio frequencies by a factor of 10. Most modern frequency lists, including the CAFL, derive from these Crane-era modifications, not Rife's originals.

The Consolidated Annotated Frequency List (CAFL) is the primary frequency database used by modern practitioners. It contains frequency sets for hundreds of conditions, compiled from multiple sources over decades. The CAFL itself notes that its frequencies are 'not well tested' and should be considered 'a starting point for research,' not validated treatment protocols.

Mortal Oscillatory Rate was Rife's term for a hypothesized frequency that he claimed could disintegrate a microorganism. Supporters often use the wine-glass analogy, but that analogy does not establish selective effects in living tissue. Independent researchers have not reproduced Rife's claimed organism-frequency catalog or established MORs as a clinical mechanism.

Plasma tube devices are more similar to Rife's original technology — they use gas-filled tubes excited by RF energy and deliver frequencies without physical contact. Contact/pad devices derive from Crane-era modifications and deliver frequencies via electrical current through electrodes on the body. Neither exactly replicates Rife's original methodology.

No. This site does not sell devices, treatments, or services. It provides historical and educational information only. We do not endorse or recommend specific products or practitioners.

No. This website presents historical and educational information only. It is not medical advice. Rife-style devices and the frequency lists collected here are not FDA-approved treatments. Consult qualified healthcare providers for medical conditions and do not delay evidence-based care.

You shouldn't trust any source unconditionally. We provide primary source citations for our claims — Smithsonian reports, Congressional records, court transcripts, newspaper archives. Verify them yourself. We distinguish between documented facts and historical claims. We acknowledge what's proven, what's reported, and what remains unverified. We include critical perspectives, like the Quekett Journal analysis of the surviving microscope.

Most primary sources we cite are publicly accessible: the Fitzgerald Report is in the Congressional Record and on the Internet Archive, the Smithsonian publication is in institutional libraries, U.S. Patent #1,727,618 is searchable in the USPTO database, and newspaper archives are available through various services. The Science Museum in London holds the surviving microscope (Inventory 1990-667).